<DOC>
	<DOCNO>NCT01393080</DOCNO>
	<brief_summary>Nimotuzumab ( hR3 ) IgG1 humanize monoclonal antibody recognize epitope locate extra cellular domain human epidermal growth factor receptor ( EGFR ) . Clinical efficacy show adult head neck cancer . This study assess efficacy safety combination Nimotuzumab administer concomitantly chemotherapy patient NSCLC . This randomized , muti-center site trial treatment .</brief_summary>
	<brief_title>Nimotuzumab Combination With Paclitaxel Liposome Carboplatin ( TP Regimen ) Advanced NSCLC Patients</brief_title>
	<detailed_description>This randomize , muti-center site trial Nimotuzumab combination Paclitaxel Liposome Carboplatin ( TP regimen ) treatment .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Signature informed consent form 2 . Ages 18 70 year old ; male female . 3 . Pathologically and/or cytologically ① patient ⅢB～Ⅳstage NSCLC ; ② patient IIIA stage NSCLC could receive operation could operate . ③ patient IIIA stage NSCLC recurrent postoperation . 4 . EGFR mRNA peripheral blood positive ELISA expression EGFR tumor tissue positive immunohistochemical staining . 5 . Functions major organ ( haemogram , heart , liver , kidney ) basically normal , White blood count ≥3.5 x 109/L neutrophil ≥1.5 x 109/L , platelet count≥100 x 109/L , hemoglobin ≥90g/L . Total bilirubin ≤1.5 time upper limit normal ( ULN ) range ; alkaline phosphatase ( ALP ) ≤ 2.5 time ULN , Transaminases AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 time ULN , serum creatinine ≤ 1.2 time ULN . 6 . With ECOG performance status 02 ; 7 . Both female male patient must use adequate method contraception . 1 . Participation clinical trial within 1 month prior inclusion trial . 2 . Previous target treatment TKI EGFR antibodies prior inclusion trial . 3 . Previous paclitaxel liposome carboplatin ( TP ) chemotherapy prior inclusion trial . 4 . With serious internal disease uncontrolled infection ; refractoriness dysentery enterospasm , intestinal obstruction . 5 . Cardiovascular disease history ( 1 ) Uncontrollable hypertension , unstable angina , heart infarction , congestive heart failure arrhythmia ( happen within 12 month prior inclusion trial ) ( 2 ) Ischemia check ECG , clinical diagnostic Heart valve disease ( 3 ) The patient Grade II ( CTC AE 3.0 ) arrhythmia , myocardial ischemia , troponin T abnormality , hypertension leave ventricular ejection fraction ＜50 % ，could include TP+ nimotuzumab test group ; 6 . With drug addition , I.e . , drugtaking , drugtaking long time ; type B hepatitis C hepatitis active stage , AIDS . 7 . Other malignant tumor , except skin basal cell carcinoma , cervical carcinoma situ , curative carcinoma prostate . 8 . With history serious allergic allergy . 9 . Patients less compliance 10 . Pregnancy , lactation , fertility use prohibit contraceptive method . 11 . Not fit clinical trial judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>nimotuzumab</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>chemotherapy</keyword>
</DOC>